Michael Henderson, M.D.
Michael Henderson, M.D., joined BridgeBio to bring genetically targeted treatments to those patients with the highest unmet need. As SVP of asset acquisition, strategy, and operations, at BridgeBio he is responsible for identifying and bringing in new technologies, furthering the overarching strategy of BridgeBio, and playing an operator role both in the parent and subsidiary companies. He has overseen the creation of 15 companies to date and is currently serving as interim CBO for QED Therapeutics. Michael is a voting board member for five of BridgeBio’s subsidiary companies and played a key role in one of BridgeBio’s portfolio companies, PellePharm, which he cofounded while in medical school. Prior to BridgeBio, he was a consultant in McKinsey & Company’s Silicon Valley Office where he served biotech clients across the US and EU. He received his B.A. from Harvard University and holds an M.D. from Stanford University. Originally from Oklahoma, he is a die-hard fan of the Oklahoma Sooners and a sworn enemy of any football team that opposes them.